Drugs / CD19&CD22 bispecific CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06735495 | Nov 2024 → Dec 2027 expected | B-cell acute lymphoblastic leukemia | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19&CD22 bispecific CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06735495 ↗ |
| Modality | Cell therapy | “CAR-T ( chimeric antigen receptor T cell) therapy” NCT06735495 ↗ |
| Route | Intravenous | “CD19\&CD22 bispecific CAR-T cells by intravenous infusion” NCT06735495 ↗ |
| Target | CD19 | “CD19 \& CD22 bispecific CAR-T cells can identify CD 19 or CD 22” NCT06735495 ↗ |
| Target | CD22 | “CD19 \& CD22 bispecific CAR-T cells can identify CD 19 or CD 22” NCT06735495 ↗ |